BusinessAvid Bioservices and Oncologie Enter Into Asset Assignment and Purchase Agreement for Avid’s PS-Targeting Program Including BavituximabBy Nasdaq OMXFeb 12, 2018, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Name Change to Avid Bioservices as Part of Transition to Dedicated Contract Development and Manufacturing Organization (CDMO)By Nasdaq OMXJan 5, 2018, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals to Present at Biotech Showcase 2018By Nasdaq OMXJan 2, 2018, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D., as President and Chief Executive OfficerBy Nasdaq OMXDec 26, 2017, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2018 and Recent DevelopmentsBy Nasdaq OMXDec 11, 2017, 9:05 PM UTC
BusinessPeregrine Pharmaceuticals, Ronin Trading and SW Investment Management Announce Settlement AgreementBy Nasdaq OMXNov 28, 2017, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Appointment of Patrick Walsh to Board of Directors of Peregrine and Avid BioservicesBy Nasdaq OMXOct 24, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid BioservicesBy Nasdaq OMXOct 19, 2017, 12:05 PM UTC
